Christopher Aker compensation by year
Regulus Therapeutics Summary Compensation Table · all 2 fiscal years held| Component | FY2022 | FY2023 |
|---|---|---|
| Salary | $357,000 | $387,700 |
| Bonus | $0 | $0 |
| Stock awards | $30,840 | $33,300 |
| Option awards | $95,913 | $475,845 |
| Non-equity incentive | $167,790 | $178,342 |
| Pension and deferred compensation | $0 | $0 |
| All other | $0 | $9,900 |
| Total | $651,543 | $1,085,087 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Regulus Therapeutics Inc. DEF 14A filed April 19, 2024, accession 0001193125-24-102883, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Regulus Therapeutics Inc. filed document, accession 0001193125-24-102883. Every figure is read from that document and cited to the page and table it appears in. Filed April 19, 2024.
Equity holdings
unvested awards at FY2023 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 131,250 | $168,000 | — |
| PSU | 11,250 | $14,400 | — |
| Option | 33,500 | — | $6.40 |
| Option | 360,938 | — | $1.36 |
| Option | 7,000 | — | $13.10 |
| Option | 34,688 | — | $1.48 |
| Option | 437 | — | $13.10 |
| Option | 2,500 | — | $9.50 |
| Option | 750 | — | $9.50 |
| Option | 4,875 | — | $15.90 |
| Option | 24,997 | — | $2.60 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Regulus Therapeutics Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.
Regulus Therapeutics’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Joseph Hagan | Chief Executive Officer | $2,575,123 |
| Christopher Aker · this page | Senior Vice President and General Counsel | $1,085,087 |
| Cris Calsada | Chief Financial Officer | $1,068,174 |
Christopher Aker's compensation dossier, Regulus Therapeutics
You have read Christopher Aker's totals and holdings. The dossier adds each equity grant Regulus Therapeutics disclosed for Christopher Aker and Regulus Therapeutics's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Regulus Therapeutics compensation record
free company briefThis page is one person within Regulus Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Regulus Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Regulus Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.